OBJECTIVES Polyethylene glycol (PEG) 3350 (MiraLAX) is currently approved for the short-
term treatment of occasional constipation. This study was designed to compare the safety …

OBJECTIVES: Clinical studies in constipated adult patients have shown that a 17-or 34-g
daily dose of polyethylene glycol (PEG) 3350 (MiraLax) is safe and effective for the treatment …

Objectives Medications often cause constipation and little data are available concerning
treatment interventions. This study was designed to evaluate the safety and efficacy of …

It is unclear how polyethylene glycol (PEG) laxatives compare with other classes of laxative
in terms of efficacy. To assess efficacy of PEG vs. placebo and active comparators in adults …

Background This study evaluated the safety and effectiveness of a new polyethylene glycol
(PEG) laxative (MiraLax, Braintree Laboratories Inc, Braintree, Mass) in 23 patients reporting …

OBJECTIVE: This study was designed to determine the efficacy and safety of a new laxative,
Braintree polyethylene glycol (PEG) laxative (Miralax, Braintree Laboratories, Braintree …

OBJECTIVE Polyethylene glycol (PEG) 3350 (MiraLax) and tegaserod (Zelnorm), a
serotonin subtype 4 receptor partial agonist, are currently approved for treatment of …

Aim: To compare standard and maximum daily doses of polyethylene glycol 3350 plus
electrolytes (Transipeg) and polyethylene glycol 4000 (Forlax) in a multicentre, double …

Background Polyethylene glycol (PEG) 3350 is a non-absorbable, non-metabolised osmotic
agent used in lavage solutions for gut cleansing. Aims To compare the efficacy of PEG and …

OBJECTIVES Constipation is common, and its treatment is unsatisfactory. Although many
agents have been tried, there are limited data to support their use. Our aim was to undertake …